Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Novo Nordisk sticks its neck out for a tech that promises oral insulin
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
Following the M&A money, by phase and therapy area
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Sanofi doubles down on Biontech
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
Christmas comes early for Agenus
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
Novo sets up antisense challenge with Staten deal
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
Tyk2 reaches tipping point
Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.
Looking for new mechanisms to cure hepatitis B
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.